Beginning around middle age, many women develop very significant
problems of moderate to severe hot flashes (vasomotor symptoms)
associated with menopause which is caused by a natural depletion of
Replacement Estrogen greatly helps the problem but oral Estrogen is
processed thru the liver which also controls blood clotting enzymes.
As a consequence the side effect of oral Estrogen are blood clots and
strokes, which while quite rare, can be fatal.
Also replacement Estrogen is associated with increased incidences of
Until now, many women would rather suffer than take the risks.
AIS has developed an estrogen replacement product (very recently
approved by the FDA and now available by prescription) called
ELESTRIN - which is administered via a Transdermal Gel which is
absorbed thru the skin - and since it is not processed in the liver -
the chance for blood clots and/or strokes are eliminated.
Also ELESTRIN has been fully approved by the FDA as the
" lowest effective dose " and the lower the dose the less chance
women have of developing breast cancer from treatment.
The gel is applied as a measured dose from an applicator (not smeared on from a tube) - is absorbed in less than a minute, leaves no film on the skin,is colorless and odorless; and once applied can not be accidentally rubbed or washed off.
AIS' Transdermal Gel can be thought of as the next generation
of "The Patch" however the patch usually causes significant skin
irritation; and often delivers irregular doses. ELESTRIN causes no
skin problems; and as a daily, measured dose - provides the proper
dose each time.
(I believe thru my significant research) is the safest and most effective product on the market today to relieve women of this most disturbing impairment to a feeling of well being and good health.
A majority of older people suffer from Overactive Bladder -
characterized by urgent, frequent, or uncontrolled urination causing
accidents and/or runs to the bathroom - which is highly inconvenient
and embarrassing. The "gold standard" medication to treat this
problem is Oxybutynin - but the problem here is also side effects-
which are mostly dry mouth, dry eye and constipation (all pretty
miserable). ANTUROL, which is now in a phase 3 (final) clinical
trial with the FDA- (after completing a phase 2 trial with wonderful
results as to efficacy and safety) also utilized AIS' transdermal
gel technology and does not enter the digestive tract and the side
effects are thus eliminated.
It is expected (as with Elestrin) - that when approved by the FDA
probably in early to mid 2009- ANTUROL will be the " lowest effective
dose " available - And one should always strive to take only enough
medication to correct or alleviate the problem - and no more.
Is an AIS Transdermal Gel product in Phase 3 FDA clinical trials
(again, after wonderful results in a phase 2 trial) to treat Women's
Sexual Dysfunction. (no, or low percentage, of "satisfying sexual
In an AAPR magazine (November/December 2007) Ms. Nancy Wartik-
wrote an article entitled: " Will There Ever Be A Pink Viagra "?
The article discussed Women's Sexual Dysfunction; waning libidos,
vaginal dryness and pain during sexual relations. The article claims
that a cure for such problems&... be: "The Holy Grail Of The
AIS' Libi-Gel should be the first prescription product approved for use in the United States to treat this problem (Procter & Gamble has a Patch product (Intrinsa) approved for use in Europe - and all my research indicates that Libi-Gel is a superior product.
RECENT NEWS PERTINENT TO THE ABOVE :
(1) Parade Magazine (supplement to many Sunday Newspapers) has a
respected featured weekly columnist, Dr. Isadore Rosenfeld. In the
December 9, 2007 magazine he reviews his opinion of the "Five Top
Health Breakthroughs of 2007" and one of the five is "A better way
to take medicine" which is "medicine delivered topically - via the skin".
(2) The November/December issue of AARP Magazine (largest
circulation in the world) features an article titled: "Will there ever
be a pink Viagra?" and advises: "if there was a drug to treat
women's sexual dysfunction, it would be the "Holy Grail" of the
Pharmaceutical industry. [Antares has a drug in phase 3 clinical trials
before the FDA which will probably be the first such approved drug in
the United States].
(3) On January 2, 2008 MSNBC carried a story which featured
Antares' Libi-Gel drug for women's sexual dysfunction in an extremely
(4) Popular television personality; Dr. Sanjay Gupta, about a year ago
discussed testosterone products and their benefits - and at the
end of the presentation discussed its potential benefits for women, and
Libi-Gel is a testosterone product.
article which disparages either Antares or its field of medicine.
OTHER AIS PLATFORMS:
AIS has an injectable division and a "fast melt" technology - described
below: In the Injectable Division AIS has four licensing agreements
with TEVA (largest generic drug company in the world) which will deliver
TEVA drugs thru AIS' devices. These drugs must be re-engineered to
work with AIS' devices and require FDA approvals (1 of which is
expected in 2008 and the 2nd & 3rd in 2009).
(1). Injection Devices (which would decrease the discomfort of
the injection and improve patient compliance).
Reusable Needle-Free Injectors (Medi-Jector VISION®) deliver
precise medication doses through high-speed, pressurized liquid
penetration of the skin without a needle. These reusable, variable-
dose devices are engineered to last for a minimum of two years and
are designed for easy use, facilitating self-injection with a
disposable syringe to assure safety and efficacy.
Disposable Mini-Needle Injectors (Vibex™) employ the same core
technology developed for the Medi-Jector VISION®, combining a
spring-powered source with a tiny hidden needle in a disposable,
single-use injection system compatible with conventional syringes.
(2). Easy Tec™ Fast Melt Oral Disintegrating Tablets (perfect
for many geriatric & pedritic applications).
Easy Tec™ fast-melt oral disintegrating tablets are designed to help
patients who experience difficulty swallowing pills, tablets or capsules,
while providing the same effectiveness as conventional oral dosage
forms. AIS' tablets feature a “disintegrant addition” that facilitates
the disintegration of an oral drug to promote quick and easy
administration in saliva without water.
FROM A BUSINESS / INVESTMENT STANDP...:
ANTARES is a publicly traded company on the American Stock
Exchange - symbol - (AIS). I did great due diligence to determine
if the company was honestly managed, is the science credible, is
the market for their products large - was the company well
funded and is the trading volume sufficient to insure liquidity,
etc. All of my research proved overwhelmingly favorable. I have
a large investment in ANTARES (as do many of my Doctor friends who
brought ANTARES to my attention and helped me with my research).
but other than as an investor, I have no relationship whatsoever
with the company.
Antares' management is honest and capable. They have excellent
resume's which can easily be verified.
ANTARES has about $13+ million dollars in cash on hand.
There are about 68 million shares outstanding, which gives it a market
capitalization of about $ 34 million dollars. Similar companies in this
field have market caps several times higher than that of ANTARES -
and I expect, when ANTARES comes to the attention of Fund
managers and the analyst community, they can pretty easily trade at
a price several times the current price. I am certain that with all
the opportunities existing for Antares, their cash position, their
patent protection, etc: the down side risk from here is extremely
ANTARES is currently covered by three prominent analysts and all
have a strong buy recommendation and a price target at least
2-4 times higher than today's price. I personally think AIS could
increase in value by 10 X within the next 12 to 18 months.
for further information and confirmation of the information contained
in this letter.